Pipeline Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Pharmaceutical TechnologyBiogen plans to pause or terminate investment in most of Apellis' legacy research programmes, while cutting some of its workforce.Immunology & InflammationRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Viridian wins FDA approval for Lumvoa for thyroid eye diseaseNext: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit Related Stories Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026 Pipeline Roche scraps two Ionis-partnered Huntington’s drugs pharminent July 9, 2026
